Germano Geno J 4

What Happened

• Geno J. Germano, a director of Precision BioSciences, received a grant of 20,979 restricted stock units (RSUs) on June 3, 2026. The reported acquisition price is $0.00 because this was an award (transaction code A) rather than a market purchase. These RSUs are derivatives that represent the right to receive shares if and when they vest.

Key Details

• Transaction date: 2026-06-03; filed on 2026-06-05 (Form 4 accession 0001628280-26-041041) — appears to be filed timely.
• Grant: 20,979 RSUs; acquisition price reported $0.00 (award/derivative).
• Shares owned after transaction: not reported in the provided filing data.
• Footnotes: F1 — each RSU equals a contingent right to one share of common stock; F2 — RSUs vest on the earlier of (i) June 3, 2027 or (ii) the day before the issuer’s next annual meeting after the grant, contingent on continued service.
• This is a compensation award (not an open-market purchase or sale).

Context

• RSUs are contingent awards that convert into actual shares only upon vesting; they are commonly used for director and executive compensation and do not represent an immediate buy or sell signal. Once vested, shares may be delivered subject to the plan’s terms (e.g., potential tax withholding), at which point they would become tradable shares.